Serum Tenascin-C Concentration in Patients With Acute Coronary Syndrome

The First Affiliated Hospital of Dalian Medical University

Status: Completed

Conditions: Acute Coronary Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02767960

LCKY2016

Details and patient eligibility

About

This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Full description

It is found that Tenascin-C plays an important role in ventricular remodeling, heart failure, aortic dissection, rheumatic heart disease and other cardiovascular diseases, which may be a new marker for the diagnosis and prognosis prediction of these diseases. However, there is few relevant studies about the Tenascin-C concentration in patients with acute coronary syndrome.This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Enrollment: 183 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

.diagnosed as acute coronary syndrome,including STEMI,non-STEMI,and UAP.

• with left ventricular ejection fraction（LVEF）>=45%
• written informed consents are obtained
• admitted within 24 hours after chest pain attacked

Exclusion criteria

• complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy
• complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
• with acute or chronic infection, surgery or trauma in the last month
• secondary hypertension, severe liver dysfunction,severe renal insufficiency
• with abnormal thyroid function or allergy to iodine agent
• refusal to sign the informed consent

Trial design

183 participants in 4 patient groups

STEMI group

Description:

The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.

NSTEMI group

Description:

The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.

UAP group

Description:

The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.

control group

Description:

15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.